Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VisAcT PET imaging in advanced NSCLC
NCT04726215Phase 2Recruiting
- Sponsor
- CellSight Technologies
- Start
- Apr 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of [18F]fluoro-arabinofuranosyl guanine in non-small cell lung cancer (NSCLC), sponsored by CellSight Technologies. Started Apr 2021; status: recruiting.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04726215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04726215.